GlaxoSmithKline Pharmaceuticals Limited announced the unaudited financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these standalone and consolidated figures on February 9, 2026. Key highlights include the standalone Profit Before Tax of ₹100,711 Lakhs for nine months, and the consolidated Profit After Tax of ₹75,812 Lakhs for the same period. The results also detail the accounting impact of recent labor code notifications.
Board Approval and Reporting Period
GlaxoSmithKline Pharmaceuticals Limited officially released its Unaudited Standalone and Consolidated Financial Results following the Board of Directors meeting held on February 9, 2026. The results pertain to the quarter ended December 31, 2025, and the nine months ended the same date.
Standalone Financial Performance (Nine Months Ended 31.12.2025)
The standalone performance showed robust profitability:
- Total Income (9M): Increased to ₹290,790 Lakhs (compared to ₹286,051 Lakhs in the previous corresponding period).
- Profit Before Exceptional Items and Tax (9M): Stood at ₹100,447 Lakhs.
- Exceptional Credit: A credit of ₹264 Lakhs was noted for the period, related to the profit on the sale of surplus residential properties.
- Profit Before Tax (9M): Reached ₹100,711 Lakhs.
- Profit After Tax (9M): Finalized at ₹73,688 Lakhs.
- EPS: Basic and diluted EPS after exceptional items was ₹43.50.
Consolidated Financial Performance (Nine Months Ended 31.12.2025)
On a consolidated basis, the Group’s performance was as follows:
- Total Income (9M): ₹293,578 Lakhs.
- Profit Before Exceptional Items and Tax (9M): ₹101,229 Lakhs.
- Exceptional Credit: The consolidated statement recognized ₹2,062 Lakhs in exceptional credit, including profit on the sale of surplus residential properties and non-operational land sites.
- Profit After Tax (9M): Totaled ₹75,812 Lakhs.
- EPS: Basic and diluted EPS after exceptional items was reported at ₹44.75.
Significant Accounting Note: Labour Code Impact
The company disclosed that the notification of four major Labour Codes by the Government on November 21, 2025, has necessitated an assessment of financial impact. Based on an actuarial valuation report, this has resulted in an incremental increase of ₹1,182 Lakhs in Employee Benefits expense for both the quarter and the nine months ended December 31, 2025, primarily due to changes in wage definition.
Segment Reporting
The company confirmed that it operates in a single reportable segment, which is Pharmaceuticals; therefore, no further segment disclosures were made.
Source: BSE
